RxDoctor Payments Data

Jessica Thasitis, APRN

Family · Columbia, SCNPI 1356601272

Payments from drug & device makers

$5,805in general payments, 2019–2025

Across 261 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$781
  • AbbVie$497
  • AstraZeneca$278
  • Phathom Pharmaceuticals, Inc.$264
  • Johnson & Johnson$264
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,76099%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,805 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$91,115
Medicare patients
105
Services billed
1,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$72,285
JanuviaSitagliptin Phosphate23$36,764
JardianceEmpagliflozin27$29,546
OzempicSemaglutide12$23,467
Repatha SureclickEvolocumab22$22,199
TrintellixVortioxetine Hydrobromide17$12,148
Breo ElliptaFluticasone/Vilanterol14$7,018
Albuterol Sulfate HfaAlbuterol Sulfate102$3,074
SynthroidLevothyroxine Sodium35$2,470
Duloxetine Hcl51$2,270
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,231
ValacyclovirValacyclovir Hcl22$2,058
Fluticasone Propionate99$1,760
Levothyroxine Sodium137$1,576
Esomeprazole Magnesium29$1,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$781$72,28559 claims
MerckJanuvia$33$36,76423 claims
Novo NordiskOzempic$1,287$23,46712 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$116$12,14817 claims
GSKBreo Ellipta$82$7,01814 claims
AbbVieSynthroid$497$2,47035 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$1,576137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →